Instructions for Credit — This activity is accredited for 1.5 continuing education credit for nurse practitioners and nurses. Participants must attend the free webinar in its entirety, watch all videos and read included materials, submit the online evaluation form and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners and nurses involved in the care of patients with hematologic malignancies.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Provide an overview of chimeric antigen receptor (CAR) T-cell therapy and the blood cancers and solid tumors under study for treatment|
|•||Explain the nurse’s role in assessment, monitoring for and managing side effects of treatment|
|•||Describe the nurse’s role in preparing patients and family members about the CART process and potential side effects of treatment|
|•||Address the need for communication with a patient’s community oncologist and healthcare team to transition care|
|•||Identify resources for the nurse, social worker and other HCPs to educate and support patients and caregivers|
Commercial Support Acknowledgement — This activity is supported by educational grants from Bristol Myers Squibb, Kite, A Gilead Company and Novartis Pharmaceuticals Corporation.
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Nurse Practitioner Credit Designation
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124676. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Please click here for test blueprint and points information.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at ProfEducation@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Sherry Adkins RN, MSN, ANP-C, Advisory Board: Celgene/Bristol Meyers Squibb
Heather DiFilippo MSN, CRNP, Janssen Preceptor; CAR T Advisory Board: Celgene/Janssen; Novartis: Speaker Bureau
Ilene Galinsky, BSN, MSN, ANPc, Consultant: AbbVie, Celgene, Pfizer, Merus, Jazz
Kathleen McDermott, RN, BSN, CAR T Speaker Bureau: Gilead/ KITE; CAR T Advisory Board: Celgene
Disclaimer — Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|Estimated time to complete activity: 1.5 hours|
|Date of initial release: January 19, 2021|
|Expiration date: January 19, 2022|
Sherry Adkins, RN, MSN, ANP-C, is an Advanced Practice Nurse with over 20 years of experience. After completing an Advanced Practice Oncology Fellowship Program at the University of Texas Health Science Center in Houston in 2008, she began working as a nurse practitioner in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center. In 2014 she began working with Dr. Sattva Neelapu in leading multiple CAR T-cell therapy clinical trials including the ZUMA-1 Registry Trial which led to the release of the first commercial CAR T-cell therapy for the treatment of lymphoma. She has been instrumental in developing a commercial program for CAR-T cell therapy and has developed expertise in the CAR T-cell arena, particularly regarding the assessment and management of toxicities.
Heather DiFilippo, MSN, CRNP, is a Nurse Practitioner in the Department of Hematology Oncology and Bone Marrow Transplant at the Hospital of the University of Pennsylvania. She has been a nurse practitioner since 2003 and specializes in hematologic malignancies as well as bone marrow transplant and immunotherapy. She has played an active role in managing patients receiving cellular therapy since 2009 and provides ongoing patient education as well as direct patient care during and after infusion. Ms. DiFilippo attended Roanoke College in Salem, Virginia where she received a Bachelor of Science in psychology, before continuing on to pursue a Bachelor of Science in nursing at Thomas Jefferson University Hospital. While working in oncology at Jefferson University Hospital, she completed her Master of Science in nursing as well. Ms. DiFilippo is a Board-Certified Adult Nurse Practitioner and licensed in Pennsylvania.
Ilene Galinsky, BSN, MSN, NP-C, is a Senior Adult Leukemia Program Research Nurse Practitioner Leukemia Program at the Dana Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital (BWH) in Boston MA. She has worked at the DFCI for 32 years, beginning as a selected nurse intern on the oncology inpatient service. After serving as Charge Nurse on the inpatient service and as a Program Nurse in Harvard’s Joint Center for Radiation Therapy, she joined the DFCI/BWH Leukemia Program as a program/research RN. After receiving her Master’s Degree in Adult Primary Care in 2004, she became the senior program research midlevel nurse practitioner in the Adult Leukemia program overseeing many aspects of clinical research activities as well as participating in the care of many patients with leukemia and related disorders.
Currently, Nurse Practitioner Galinsky, is employed full time as the Senior Program Research Nurse Practitioner in the DFCI/BWH adult Leukemia Program where she has implemented a collaboration meeting with pharmacy and nursing at both the inpatient and outpatient setting. In addition, she was recently instrumental in assisting in the establishment of the strategic team for CAR T cells. Currently a part of a research task force looking into safety and educational and communication programs between the research team and the clinical teams. She serves as the co-chair of the Alliance (national oncology trial cooperative group) Oncology Nurse Committee, as well as nurse liaison to the Leukemia, Myeloma, and Transplant Alliance Committees. She is a member of American Society of Hematology and Oncology Nursing Society. She has recently completed her service on the oncology board of the ABIM, serving as the non MD representative.
Kathleen McDermott, RN, BSN, OCN®, BMTCN®, is a Staff Nurse with 38 years of experience in the Dana-Farber/Brigham and Women’s Cancer Care Program. Since 2000, she has been a lymphoma program/ research nurse coordinating autologous stem cell transplants and in 2015 added CAR T research trials. In 2018 when commercial products come to market, she accepted the DFCI inaugural position as the Immune Effector Cell (IEC) Program Nurse Navigator. Kathleen played an integral role in the development of DFCI/BWH commercial CAR T program.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: www.LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: www.LLS.org/Research
CART Fact Sheet for HCPs: www.LLS.org/Booklets
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
CART specific resources: www.LLS.org/CART
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at 800-955-4572.